NCT05819892 2026-03-11
Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
Clinical Trials
21 trialsNCT04068753 2026-02-10
STAR
University of Oklahoma
Phase 2 Active not recruiting
NCT04774419 2026-02-03
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07336147 2026-01-14
Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma
Chang Gung Memorial Hospital
Phase 2 Recruiting
NCT06238635 2026-01-13
Dostarlimab and Cobolimab in Advanced Cervical Cancer
Beth Israel Deaconess Medical Center
Phase 2 Active not recruiting
NCT04673448 2026-01-09
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
University of Washington
Phase 1 Active not recruiting
NCT03955978 2026-01-06
TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer
Washington University School of Medicine
Phase 1 Active not recruiting
NCT03651206 2025-12-19
ROCSAN
ARCAGY/ GINECO GROUP
Phase 2/3 Recruiting
NCT05201547 2025-12-04
DOMENICA
ARCAGY/ GINECO GROUP
Phase 3 Active not recruiting
NCT07115927 2025-08-19
RODEO
University College, London
Phase 2 Not yet recruiting
NCT06023862 2025-06-15
DOVE
Yonsei University
Phase 2 Recruiting
NCT07013851 2025-06-10
NADIA
Grupo EspaƱol de InvestigaciĆ³n en CĆ”ncer de Ovario
Phase 2 Not yet recruiting
NCT03833479 2025-05-21
ATOMICC
Grupo EspaƱol de InvestigaciĆ³n en CĆ”ncer de Ovario
Phase 2 Active not recruiting
NCT05559879 2025-05-04
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
University of Alabama at Birmingham
Phase 1/2 Recruiting
NCT06385548 2025-04-01
LiDer
Vall d'Hebron Institute of Oncology
Phase 1/2 Withdrawn
NCT05728814 2024-02-23
DORA
Grupo EspaƱol de InvestigaciĆ³n en CĆ”ncer de Ovario
Unknown
NCT03016338 2024-01-30
Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer
University Health Network, Toronto
Phase 2 Unknown
NCT05065021 2024-01-17
Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor
University Health Network, Toronto
Phase 2 Unknown
NCT05405192 2023-02-28
Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia
University of Miami
Phase 2 Withdrawn
NCT04679064 2021-08-27
NItCHE-MITO33
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 3 Unknown
NCT03806049 2021-07-15
Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 3 Withdrawn